Europe
Loading...
| Exchange | Trading Currency | Ticker | Listing Date | SEDOL | Net Asset Value (NAV) | Shares Outstanding | Net Assets |
|---|---|---|---|---|---|---|---|
As of recent Month End & Quarter End (31 Dec 2025) | ETF | Index | Difference |
|---|---|---|---|
| 1 Year | 18.86% | 19.35% | -0.49% |
| 3 Years | -3.04% | -2.53% | -0.51% |
| Since Inception | -14.25% | -13.83% | -0.42% |
| Net Assets (%) | Ticker | Name | Country | SEDOL | Market Price | Shares Held | Market Value |
|---|---|---|---|---|---|---|---|
| Sector | Weight (%) | |
|---|---|---|
| Health Care | 100.0 |
| Country | Weight (%) | |
|---|---|---|
| United States | 82.9 | |
| Netherlands | 4.8 | |
| Germany | 3.5 | |
| Switzerland | 3.3 | |
| Britain | 2.1 | |
| Singapore | 1.8 | |
| China | 1.6 |
| Industry | Weight (%) | |
|---|---|---|
| Pharmaceuticals, Biotechnology & Life Sciences | 91.3 | |
| Health Care Equipment & Services | 8.7 |
| Return on Equity | -19.60% | |
| Average Market Cap | 49,806 M | |
| 2025 | 2026 | |
| Price to Earnings | -21.32 | -31.58 |
| Price to Book | 5.57 | 6.99 |
| Type of Loan Security | USD Cash | Sovereign Debt |
|---|---|---|
| U.S. Equity and Corporate Securities (including ADRs) | 102% | 105% |
| U.S. Treasury Securities | 105% | 105% |
| U.S. Treasury and Agency Securities | 102% | 105% |
| Exchange | Trading Currency | Ticker | Listing Date | SEDOL | Net Asset Value (NAV) | Shares Outstanding | Net Assets |
|---|---|---|---|---|---|---|---|
| London Stock Exchange | USD | GNOM LN | 04 Nov 2021 | BP49D86 | $8.54 (4.15%) | 2,420,000 | $20,655,980.80 |
| London Stock Exchange | GBP | GNOG LN | 04 Nov 2021 | BP49D97 | -- | -- | -- |
| Borsa Italiana | EUR | GNOM IM | 18 Nov 2021 | BP49DD1 | -- | -- | -- |
| Deutsche Börse Xetra | EUR | GN0M GY | 11 Nov 2021 | BP49DB9 | -- | -- | -- |
| SIX Swiss Exchange | CHF | GNOM SW | 06 Dec 2021 | BP49DC0 | -- | -- | -- |
| Net Assets (%) | Ticker | Name | Country | SEDOL | Market Price ($) | Shares Held | Market Value ($) |
|---|---|---|---|---|---|---|---|
| 6.37 | ARWR | ARROWHEAD PHARMACEUTICALS IN | US | BYQBFJ8 | 70.81 | 18,575 | 1,315,295.75 |
| 5.62 | GH | GUARDANT HEALTH INC | US | BFXC911 | 112.33 | 10,329 | 1,160,256.57 |
| 5.59 | ILMN | ILLUMINA INC | US | 2613990 | 147.11 | 7,854 | 1,155,401.94 |
| 5.22 | MRNA | MODERNA INC | US | BGSXTS3 | 35.66 | 30,228 | 1,077,930.48 |
| 5.04 | PRAX | PRAXIS PRECISION MEDICINES I | US | BQ721R4 | 272.90 | 3,815 | 1,041,113.50 |
| 4.66 | NTRA | NATERA INC | US | BYQRG48 | 248.74 | 3,872 | 963,121.28 |
| 4.20 | BMRN | BIOMARIN PHARMACEUTICAL INC | US | 2437071 | 60.07 | 14,436 | 867,170.52 |
| 4.07 | VRTX | VERTEX PHARMACEUTICALS INC | US | 2931034 | 468.38 | 1,794 | 840,273.72 |
| 3.82 | TECH | BIO-TECHNE CORP | US | BSHZ3Q0 | 65.28 | 12,073 | 788,125.44 |
| 3.76 | RNA | AVIDITY BIOSCIENCES INC | US | BMWHPY1 | 72.25 | 10,750 | 776,687.50 |
The Global X Genomics & Biotechnology UCITS ETF (GNOM LN) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.
